Viatris

htm EX-99.1 Document Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global Business Positive Results From Five Phase 3 Data Readouts This Year Reinforce Continued Momentum of Late-Stage Pipeline Returns More Than $630 Million of Capital to Shareholders Year-to-Date Including $350 Million in Share Buybacks Reiterates 2025 Financial Guidance Ranges Across all Metrics and Expects to be in the Top Half of the Range for Total Revenues and Adjusted EPS 1 PITTSBURGH August 7, 2025 Viatris Inc.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

GAAP Net Cash Provided by Operating Activities $ 219.7 $ 379.1 (42)% Capital Expenditures 52.9 58.8 (10)% Free Cash Flow (2)(3) $ 166.8 $ 320.3 (48)% ___________ (1) See Certain Key Terms and Presentation Matters in this release for more information.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

GAAP Net Cash Provided by Operating Activities $ 755.2 $ 993.7 (24)% Capital Expenditures 95.5 108.6 (12)% Free Cash Flow (2)(4) $ 659.7 $ 885.1 (25)% ___________ (1) See Certain Key Terms and Presentation Matters in this release for more information.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Year-to-date, the Company returned more than $630 million of capital to shareholders, including $350 million in share repurchases.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

The Company continues to expect $500 million to $650 million in total share repurchases in 2025 and to be opportunistic with cash available throughout the year.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

GAAP diluted EPS, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, future share repurchases, and other contingencies, such as changes to contingent consideration, acquired IPR D and certain other gains or losses, including for the fair value accounting for non-marketable equity investments, as well as related income tax accounting, because certain of these items have not occurred, are out of the Company s control, and or cannot be reasonably predicted without unreasonable effort.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Executive Commentary We delivered a strong second quarter and continued to make meaningful progress against our key 2025 strategic priorities, said Scott A.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

We are progressing our enterprise-wide strategic review and continue to return significant capital to shareholders.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

We remain focused on driving commercial execution, investing in strategic accretive in-market business development opportunities and positioning Viatris for sustainable growth in 2026 and beyond.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Phentolamine Ophthalmic Solution (MR-141) The Company announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia, the gradual loss of the eyes ability to focus on nearby objects.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

4 Capital Allocation The Company is reaffirming its commitment to prioritizing returning capital to shareholders in 2025 as previously stated.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

2025 financial guidance ranges as provided on August 7, 2025, exclude the impact of any acquisition and divestiture-related transaction costs, including taxes ( transaction-related costs ), acquired IPR D for unsigned deals, and any potential impact of future tariffs and trade restrictions as they cannot be reasonably forecasted.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

GAAP diluted EPS, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, future share repurchases, and other contingencies, such as changes to contingent consideration, acquired IPR D and certain other gains or losses, including for the fair value accounting for non-marketable equity investments, as well as related income tax accounting, because certain of these items have not occurred, are out of the Company s control, and or cannot be reasonably predicted without unreasonable effort.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

2025 financial guidance does not currently include any potential adverse impact from future tariffs and trade restrictions.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

2025 Financial Guidance as provided on May 8, 2025 did not include any potential adverse impact from future tariffs and trade restrictions, which we were unable to predict at that time and could be material.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025

GAAP diluted EPS, respectively, because it was unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, future share repurchases, and other contingencies, such as changes to contingent consideration, acquired IPR D and certain other gains or losses, including for the fair value accounting for non-marketable equity investments, as well as related income tax accounting, because certain of these items had not occurred, were out of the Company s control, and or could not be reasonably predicted without unreasonable effort.

SEC original ↗Viatris — Earnings release (8-K exhibit)EX-99Aug 7, 2025